Last updated: 2026-09-16 13:20:40. Prices reflect the latest pre-market trading data. Stock price data is sourced from Massive.
Arcturus Therapeutics Holdings Inc. (ARCT) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $15,92, with a market capitalisation of $434,59M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $5,50 to $24,17. This page covers its latest market performance, valuation, price trends and company information.
$434,59M | |
$15,65 | |
$129,71 | |
$4,11 | |
$15,84 | |
7,07K | |
861,39K | |
-- | |
$24,17 | |
$5,50 | |
-- | |
-- |
Arcturus Therapeutics Holdings Inc. (ARCT) is trading at $15,92 in pre-market trading as of 2026-09-16 13:17:00, up 0,47% ($0,07) from the previous close of $15,84
Pre-market trading shows how investors are pricing ARCT before the regular session opens. The current pre-market price is near the previous close, indicating positive early trading sentiment.
Over the past seven days, Arcturus Therapeutics Holdings Inc. (ARCT) moved from $15,82 to $15,92, representing a gain of 0,60% ($0,09).
The stock traded between $13,12 and $16,02 during the period. The latest price is near the upper end of the 7-day range, indicating moderate upward.
The average daily volume was 641,74 thousand shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 55,8%
ARCT is currently trading at $15,92, placing it 55,8% of the way from its 52-week low of $5,50 to its 52-week high of $24,17. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Arcturus Therapeutics Holdings Inc is an RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases. It operates in one business segment, which includes all activities related to the discovery, development, and commercialization of messenger RNA medicines. The company's pipeline includes LUNAR-OTC and LUNAR-CF. Its Vaccine candidates include LUNAR-FLU, KOSTAIVE XBB.1.5, KOSTAIVE, and Others.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 111 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Arcturus Therapeutics Holdings Inc. (ARCT) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.